Recent development of cyclic amide (pyridone/lactam) moiety containing heterocycles as protein kinase inhibitors

Current Medicinal Chemistry

Volumn 17, Issue 3, 2010, Pages 234-253

  Wei, Linyi ^a   Malhotra, Sanjay V ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Cancer; Cyclic amide (pyridone lactam); High throughput screenings; Hydroxyfasudil; Kinase biased library; Protein kinase inhibitor; Pyridone 6; Staurosporine

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 4' DEMETHYLAMINO 4' HYDROXYSTAUROSPORINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 7 HYDROXYSTAUROSPORINE; ADENINE; ADENOSINE TRIPHOSPHATE; AMIDE; CEP 1347; CEP 751; CMP 54; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; DASATINIB; ERLOTINIB; FASUDIL; GEFITINIB; HETEROCYCLIC COMPOUND; HYDROXYFASUDIL; IMATINIB; K 252A; K 252B; K 252C; LACTAM; LAPATINIB; LESTAURTINIB; MIDOSTAURIN; MLP 52; MLR 52; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; NILOTINIB; NSC 655694; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; REBECCAMYCIN; RK 286; SB 218078; SORAFENIB; STAUROSPORINE; SUNITINIB; TAN 1303A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; HIGH THROUGHPUT SCREENING; HINGE REGION; HUMAN; HYDROGEN BOND; KIDNEY CARCINOMA; MAST CELL LEUKEMIA; MASTOCYTOSIS; NEOPLASM; REACTION ANALYSIS; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

HETEROCYCLIC COMPOUNDS; HUMANS; LACTAMS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIDONES;

EID: 77149158185     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790149747     Document Type: Review

References (170)

1. Hughes, B. 2008 FDA drug approvals. Nat. Rev. Drug Discov., 2009, 8, 93-96.
2. Jones, S.; Zhang, X.; Parsons, D. W.; Lin Jimmy, C.-H.; Leary Rebecca, J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S.-M.; Fu, B.; Lin, M.-T.; Calhoun Eric, S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D.R.; Hidalgo, M.; Leach, S.D.; Klein Alison, P.; Jaffee Elizabeth, M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman James, R.; Kern, S.E.; Hruban Ralph, H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 2008, 321, 1801-1806.
3. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A., Jr.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K.; Shinjo, S. M.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008, 321, 1807-1812.
4. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455, 1061-1068.
5. Jones, D. Pathways to cancer therapy. Nat. Rev. Drug Discov., 2008, 7, 875-876.
6. Dalton, W. S.; Friend, S. H. Cancer biomarkers - an invitation to the table. Science, 2006, 312, 1165-1168.
7. Lapenna, S.; Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov., 2009, 8, 547-566.
8. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov., 2002, 1, 309-315.
9. Faivre, S.; Djelloul, S.; Raymond, E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin. Oncol., 2006, 33, 407-420.
10. Vieth, M.; Higgs, R. E.; Robertson, D. H.; Shapiro, M.; Gragg, E. A.; Hemmerle, H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta Proteins Proteom., 2004, 1697, 243-257.
11. Walker, I.; Newell, H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov., 2009, 8, 15-16.
12. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol., 2006, 2, 358-364.
13. Johnson, L. N. Protein kinase inhibitors: contributions from structure to clinical compounds. Q. Rev. Biophys., 2009, 42, 1-40.
14. Johnson, L. N.; Lowe, E. D.; Noble, M. E.; Owen, D. J. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett., 1998, 430, 1-11.
15. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science, 2002, 298, 1912-1934.
16. Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther., 1999, 82, 195-206.
17. Cherry, M.; Williams, D. H. Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. Curr. Med. Chem., 2004, 11, 663-673.
18. Forlani, L.; Cristoni, G.; Boga, C.; Todesco, P. E.; Del Vecchio, E.; Selva, S.; Monari, M. Reinvestigation of the tautomerism of some substituted 2-hydroxypyridines. ARKIVOC, 2002, 198-215.
19. Voegeli, U.; Von Philipsborn, W. Carbon-13 NMR spectroscopy. IV. Carbon-13 and proton NMR spectroscopic studies on the structure of N-methyl-3-pyridone and 3-hydroxypyridine. Org. Magn. Resonance, 1973, 5, 551-559.
20. Specker, H.; Gawrosch, H. Ultraviolet absorption of benzotriazoles, pyridones and their salts. Ber. Dtsch. Chem. Ges. B, 1942, 75B, 1338-1348.
21. Leis, D. G.; Curran, B. C. Electric moments of some gamma - substituted pyridines. J. Am. Chem. Soc., 1945, 67, 79-81.
22. Albert, A.; Phillips, J. N. Ionization constants of heterocyclic substances. II. Hydroxy-derivatives of nitrogenous six-membered ring-compounds. J. Chem. Soc., 1956, 1294-1304.
23. Cox, R. H.; Bothner-By, A. A. Proton magnetic resonance spectra of tautomeric substituted pyridines and their conjugate acids. J. Phys. Chem., 1969, 73, 2465-2468.
24. Aksnes, D. W.; Kryvi, H. Substituent and solvent effects in the proton magnetic resonance (PMR) spectra of six 2-substituted pyridines. Acta Chem. Scand., 1972, 26, 2255-2266.
25. Aue, D. H.; Betowski, L. D.; Davidson, W. R.; Bowers, M. T.; Beak, P.; Lee, J. Gas-phase basicities of amides and imidates. Estimation of protomeric equilibrium constants by the basicity method in the gas phase. J. Am. Chem. Soc., 1979, 101, 1361-1368.
26. Frank, J.; Katritzky, A. R. Tautomeric pyridines. Part XV. Pyridone-hydroxypyridine equilibriums in solvents of differing polarity. J. Chem. Soc., Perkin Trans. 2, 1976, 1428-1431.
27. Honma, T.; Hayashi, K.; Aoyama, T.; Hashimoto, N.; Machida, T.; Fukasawa, K.; Iwama, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Iwasawa, Y.; Hayama, T.; Nishimura, S.; Morishima, H. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem., 2001, 44, 4615-4627.
28. Honma, T.; Yoshizumi, T.; Hashimoto, N.; Hayashi, K.; Kawanishi, N.; Fukasawa, K.; Takaki, T.; Ikeura, C.; Ikuta, M.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S.; Morishima, H. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J. Med. Chem., 2001, 44, 4628-4640.
29. Ikuta, M.; Kamata, K.; Fukasawa, K.; Honma, T.; Machida, T.; Hirai, H.; Suzuki-Takahashi, I.; Hayama, T.; Nishimura, S. Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J. Biol. Chem., 2001, 276, 27548-27554.
30. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res., 2003, 9, 327-337.
31. Krug, M.; Hilgeroth, A. Recent advances in the development of multi-kinase inhibitors. Mini Rev. Med. Chem., 2008, 8, 1312-1327.
32. Goodman, V. L.; Rock, E. P.; Dagher, R.; Ramchandani, R. P.; Abraham, S.; Gobburu, J. V.; Booth, B. P.; Verbois, S. L.; Morse, D. E.; Liang, C. Y.; Chidambaram, N.; Jiang, J. X.; Tang, S.; Mahjoob, K.; Justice, R.; Pazdur, R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res., 2007, 13, 1367-1373.
33. Rock, E. P.; Goodman, V.; Jiang, J. X.; Mahjoob, K.; Verbois, S. L.; Morse, D.; Dagher, R.; Justice, R.; Pazdur, R. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist, 2007, 12, 107-113.
34. Lin, N. H.; Xia, P.; Kovar, P.; Park, C.; Chen, Z.; Zhang, H.; Rosenberg, S. H.; Sham, H. L. Synthesis and biological evaluation of 3-ethylidene-1,3- dihydro-indol-2-ones as novel checkpoint 1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 421-426.
35. Motzer, R. J.; Hoosen, S.; Bello, C. L.; Christensen, J. G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs, 2006, 15, 553-561.
36. Deeks, E. D.; Keating, G. M. Sunitinib. Drugs, 2006, 66, 2255-2266; discussion 2267-2268.
37. Omura, S.; Iwai, Y.; Hirano, A.; Nakagawa, A.; Awaya, J.; Tsuchya, H.; Takahashi, Y.; Masuma, R. A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J. Antibiot. (Tokyo), 1977, 30, 275-282.
38. Tamaoki, T.; Nomoto, H.; Takahashi, I.; Kato, Y.; Morimoto, M.; Tomita, F. Staurosporine, a potent inhibitor of phospholipid/ Ca++dependent protein kinase. Biochem. Biophys. Res. Commun., 1986, 135, 397-402.
39. Prudhomme, M. Rebeccamycin analogues as anti-cancer agents. Eur. J. Med. Chem., 2003, 38, 123-140.
40. Gribble, G. W.; Berthel, S. J. A survey of indolo[2,3-a]carbazole alkaloids and related natural products. Stud. Nat. Prod. Chem., 1993, 12, 365-409.
41. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol., 2008, 26, 127-132.
42. Takahashi, I.; Saitoh, Y.; Yoshida, M.; Sano, H.; Nakano, H.; Morimoto, M.; Tamaoki, T. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J. Antibiot. (Tokyo), 1989, 42, 571-576.
43. Akiyama, T.; Yoshida, T.; Tsujita, T.; Shimizu, M.; Mizukami, T.; Okabe, M.; Akinaga, S. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res., 1997, 57, 1495-1501.
44. Akiyama, T.; Sugiyama, K.; Shimizu, M.; Tamaoki, T.; Akinaga, S. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation. Jpn. J. Cancer Res., 1999, 90, 1364-1372.
45. Bhonde, M. R.; Hanski, M. L.; Magrini, R.; Moorthy, D.; Muller, A.; Sausville, E. A.; Kohno, K.; Wiegand, P.; Daniel, P. T.; Zeitz, M.; Hanski, C. The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein. Oncogene, 2005, 24, 148-156.
46. Amornphimoltham, P.; Sriuranpong, V.; Patel, V.; Benavides, F.; Conti, C. J.; Sauk, J.; Sausville, E. A.; Molinolo, A. A.; Gutkind, J. S. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin. Cancer Res., 2004, 10, 4029-4037.
47. Kondapaka, S. B.; Zarnowski, M.; Yver, D. R.; Sausville, E. A.; Cushman, S. W. 7-hydroxystaurosporine (UCN-01) inhibition of Akt Thr308 but not Ser473 phosphorylation: a basis for decreased insulin-stimulated glucose transport. Clin. Cancer Res., 2004, 10, 7192-7198.
48. Komander, D.; Kular, G. S.; Bain, J.; Elliott, M.; Alessi, D. R.; Van Aalten, D. M. Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem. J., 2003, 375, 255-262.
49. Akinaga, S.; Nomura, K.; Gomi, K.; Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 1993, 32, 183-189.
50. Bunch, R. T.; Eastman, A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res., 1996, 2, 791-797.
51. Hsueh, C. T.; Kelsen, D.; Schwartz, G. K. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin. Cancer Res., 1998, 4, 2201-2206.
52. Wang, Q.; Fan, S.; Eastman, A.; Worland, P. J.; Sausville, E. A.; O'Connor, P. M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst., 1996, 88, 956-965.
53. Zhao, B.; Bower, M. J.; McDevitt, P. J.; Zhao, H.; Davis, S. T.; Johanson, K. O.; Green, S. M.; Concha, N. O.; Zhou, B. B. Structural basis for Chk1 inhibition by UCN-01. J. Biol. Chem., 2002, 277, 46609-46615.
54. Dees, E. C.; Baker, S. D.; O'Reilly, S.; Rudek, M. A.; Davidson, S. B.; Aylesworth, C.; Elza-Brown, K.; Carducci, M. A.; Donehower, R. C. A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin. Cancer Res., 2005, 11, 664-671.
55. Kortmansky, J.; Shah, M. A.; Kaubisch, A.; Weyerbacher, A.; Yi, S.; Tong, W.; Sowers, R.; Gonen, M.; O'Reilly, E.; Kemeny, N.; Ilson, D. I.; Saltz, L. B.; Maki, R. G.; Kelsen, D. P.; Schwartz, G. K. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J. Clin. Oncol., 2005, 23, 1875-1884.
56. Sampath, D.; Cortes, J.; Estrov, Z.; Du, M.; Shi, Z.; Andreeff, M.; Gandhi, V.; Plunkett, W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood, 2006, 107, 2517-2524.
57. Fabbro, D.; Ruetz, S.; Bodis, S.; Pruschy, M.; Csermak, K.; Man, A.; Campochiaro, P.; Wood, J.; O'Reilly, T.; Meyer, T. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des., 2000, 15, 17-28.
58. Weisberg, E.; Boulton, C.; Kelly, L. M.; Manley, P.; Fabbro, D.; Meyer, T.; Gilliland, D. G.; Griffin, J. D. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell, 2002, 1, 433-443.
59. Fabbro, D.; Buchdunger, E.; Wood, J.; Mestan, J.; Hofmann, F.; Ferrari, S.; Mett, H.; O'Reilly, T.; Meyer, T. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol. Ther., 1999, 82, 293-301.
60. Utz, I.; Hofer, S.; Regenass, U.; Hilbe, W.; Thaler, J.; Grunicke, H.; Hofmann, J. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int. J. Cancer, 1994, 57, 104-110.
61. Utz, I.; Spitaler, M.; Rybczynska, M.; Ludescher, C.; Hilbe, W.; Regenass, U.; Grunicke, H.; Hofmann, J. Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700. Int. J. Cancer, 1998, 77, 64-69.
62. Beltran, P. J.; Fan, D.; Fidler, I. J.; O'Brian, C. A. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. Biochem. Pharmacol., 1997, 53, 245-247.
63. Levis, M.; Beran, M.; Baer, M. R.; Erba, H. P.; Cripe, L.; Smith B.D.; Coutre, S.; Advani, A.; Perl, A.; Devetten, M.; Stuart, R.; Tallman, MM. S.; Brown, P.; Tremmel, L.; Small, D..A Randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 Inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition. ASH Annual Meeting Abstracts, 2005, 106, 403.
64. Stone, R. M.; Paquette, R.; Schiller, G.; Schiffer, C. A.; Ehninger, G.; Fischer, T.; Cortes, J.; Kantarjian, H.; DeAngelo, D. A.; Yu, R.; Zhang, L.; Cohen; P. S.; Wang, Y.; Phillips, P.; Giles, F. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML. ASH Annual Meeting Abstracts, 2005, 106, 404.
65. Smith, B. D.; Levis, M.; Beran, M.; Giles, F.; Kantarjian, H.; Berg, K.; Murphy, K. M.; Dauses, T.; Allebach, J.; Small, D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood, 2004, 103, 3669-3676.
66. Stone, R. M.; DeAngelo, D. J.; Klimek, V.; Galinsky, I.; Estey, E.; Nimer, S. D.; Grandin, W.; Lebwohl, D.; Wang, Y.; Cohen, P.; Fox, E. A.; Neuberg, D.; Clark, J.; Gilliland, D. G.; Griffin, J. D. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 2005, 105, 54-60.
67. Kase, H.; Iwahashi, K.; Matsuda, Y. K-252a, a potent inhibitor of protein kinase C from microbial origin. J. Antibiot. (Tokyo), 1986, 39, 1059-1065.
68. Yasuzawa, T.; Iida, T.; Yoshida, M.; Hirayama, N.; Takahashi, M.; Shirahata, K.; Sano, H. The structures of the novel protein kinase C inhibitors K-252a, b, c and d. J. Antibiot. (Tokyo), 1986, 39, 1072-1078.
69. Cai, Y.; Fredenhagen, A.; Hug, P.; Peter, H. H. The staurosporine producing strain Streptomyces longisporoflavus produces metabolites related to K-252a. Proposal for biosynthetic intermediates of K-252a. J. Antibiot. (Tokyo), 1996, 49, 1060-1062.
70. Knapper, S.; Burnett, A. K.; Littlewood, T.; Kell, W. J.; Agrawal, S.; Chopra, R.; Clark, R.; Levis, M. J.; Small, D. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood, 2006, 108, 3262-3270.
71. Mucke, H. A. CEP-1347 (Cephalon). IDrugs, 2003, 6, 377-383.
72. Murakata, C.; Kaneko, M.; Gessner, G.; Angeles, T. S.; Ator, M. A.; O'Kane, T. M.; McKenna, B. A.; Thomas, B. A.; Mathiasen, J. R.; Saporito, M. S.; Bozyczko-Coyne, D.; Hudkins, R. L. Mixed lineage kinase activity of indolocarbazole analogues. Bioorg. Med. Chem. Lett., 2002, 12, 147-150.
73. Kaneko, M.; Saito, Y.; Saito, H.; Matsumoto, T.; Matsuda, Y.; Vaught, J. L.; Dionne, C. A.; Angeles, T. S.; Glicksman, M. A.; Neff, N. T.; Rotella, D. P.; Kauer, J. C.; Mallamo, J. P.; Hudkins, R. L.; Murakata, C. Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis( alkoxymethyl)-K-252a derivatives. J. Med. Chem., 1997, 40, 1863-1869.
74. Gingrich, D. E.; Reddy, D. R.; Iqbal, M. A.; Singh, J.; Aimone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Ator, M. A.; Meyer, S. L.; Robinson, C.; Ruggeri, B. A.; Dionne, C. A.; Vaught, J. L.; Mallamo, J. P.; Hudkins, R. L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5- ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem., 2003, 46, 5375-5388.
75. Bush, J. A.; Long, B. H.; Catino, J. J.; Bradner, W. T.; Tomita, K. Production and biological activity of rebeccamycin, a novel antitumor agent. J. Antibiot. (Tokyo), 1987, 40, 668-678.
76. Pereira, E. R.; Belin, L.; Sancelme, M.; Prudhomme, M.; Ollier, M.; Rapp, M.; Severe, D.; Riou, J. F.; Fabbro, D.; Meyer, T. Structure-activity relationships in a series of substituted indolocarba zoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J. Med. Chem., 1996, 39, 4471-4477.
77. Dowlati, A.; Hoppel, C. L.; Ingalls, S. T.; Majka, S.; Li, X.; Sedransk, N.; Spiro, T.; Gerson, S. L.; Ivy, P.; Remick, S. C. Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. J. Clin. Oncol., 2001, 19, 2309-2318.
78. Tolcher, A. W.; Eckhardt, S. G.; Kuhn, J.; Hammond, L.; Weiss, G.; Rizzo, J.; Aylesworth, C.; Hidalgo, M.; Patnaik, A.; Schwartz, G.; Felton, S.; Campbell, E.; Rowinsky, E. K. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J. Clin. Oncol., 2001, 19, 2937-2947.
79. Merchant, J.; Tutsch, K.; Dresen, A.; Arzoomanian, R.; Alberti, D.; Feierabend, C.; Binger, K.; Marnoccha, R.; Thomas, J.; Cleary, J.; Wilding, G. Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats. Clin. Cancer Res., 2002, 8, 2193-2201.
80. Goel, S.; Wadler, S.; Hoffman, A.; Volterra, F.; Baker, C.; Nazario, E.; Ivy, P.; Silverman, A.; Mani, S. A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer. Invest. New Drugs, 2003, 21, 103-107.
81. Hussain, M.; Vaishampayan, U.; Heilbrun, L. K.; Jain, V.; Lo-Russo, P. M.; Ivy, P.; Flaherty, L. A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer. Invest. New Drugs, 2003, 21, 465-471.
82. Ricart, A. D.; Hammond, L. A.; Kuhn, J. G.; Takimoto, C. H.; Goetz, A.; Forouzesh, B.; Forero, L.; Ochoa-Bayona, J. L.; Berg, K.; Tolcher, A. W.; Rowinsky, E. K. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors. Clin. Cancer Res., 2005, 11, 8728-8736.
83. Burstein, H. J.; Overmoyer, B.; Gelman, R.; Silverman, P.; Savoie, J.; Clarke, K.; Dumadag, L.; Younger, J.; Ivy, P.; Winer, E. P. Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest. New Drugs, 2007, 25, 161-164.
84. Langevin, A. M.; Bernstein, M.; Kuhn, J. G.; Blaney, S. M.; Ivy, P.; Sun, J.; Chen, Z.; Adamson, P. C. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer, 2008, 50, 577-580.
85. Borthakur, G.; Alvarado, Y.; Ravandi-Kashani, F.; Cortes, J.; Estrov, Z.; Faderl, S.; Ivy, P.; Bueso-Ramos, C.; Nebiyou Bekele, B.; Giles, F. Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer, 2008, 113, 360-366.
86. Sanchez, C.; Mendez, C.; Salas, J. A. Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. Nat. Prod. Rep., 2006, 23, 1007-1045.
87. Fabre, S.; Prudhomme, M.; Rapp, M. Protein kinase C inhibitors; structure-activity relationships in K252c-related compounds. Bioorg. Med. Chem., 1993, 1, 193-196.
88. Anizon, F.; Moreau, P.; Sancelme, M.; Voldoire, A.; Prudhomme, M.; Ollier, M.; Severe, D.; Riou, J. F.; Bailly, C.; Fabbro, D.; Meyer, T.; Aubertin, A. M. Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin. Bioorg. Med. Chem., 1998, 6, 1597-1604.
89. Yang, S. M.; Malaviya, R.; Wilson, L. J.; Argentieri, R.; Chen, X.; Yang, C.; Wang, B.; Cavender, D.; Murray, W. V. Simplified staurosporine analogs as potent JAK3 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 326-331.
90. Funato, N.; Takayanagi, H.; Konda, Y.; Toda, Y.; Harigaya, Y.; Iwai, Y.; Omura, S. Absolute configuration of staurosporine by x-ray analysis. Tetrahedron Lett., 1994, 35, 1251-1254.
91. Link, J. T.; Raghavan, S.; Danishefsky, S. J. First Total Synthesis of Staurosporine and ent-Staurosporine. J. Am. Chem. Soc., 1995, 117, 552-553.
92. Link, J. T.; Raghavan, S.; Gallant, M.; Danishefsky, S. J.; Chou, T. C.; Ballas, L. M. Staurosporine and ent-Staurosporine: The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles. J. Am. Chem. Soc., 1996, 118, 2825-2842.
93. Prudhomme, M. Staurosporines and structurally related indolocarbazoles as antitumor agents. Anticancer Agents Nat. Prod., 2005, 499-517.
94. Kaneko, T.; Wong, H.; Okamoto, K. T.; Clardy, J. Two synthetic approaches to rebeccamycin. Tetrahedron Lett., 1985, 26, 4015-4018.
95. Joyce, R. P.; Gainor, J. A.; Weinreb, S. M. Synthesis of the aromatic and monosaccharide moieties of staurosporine. J. Org. Chem., 1987, 52, 1177-1185.
96. Brenner, M.; Rexhausen, H.; Steffan, B.; Steglich, W. Pigments of fungi, 57. Synthesis of arcyriarubin B and related bisindolylmaleimides. Tetrahedron, 1988, 44, 2887-2892.
97. Faul, M. M.; Winneroski, L. L.; Krumrich, C. A. A New, Efficient Method for the Synthesis of Bisindolylmaleimides. J. Org. Chem., 1998, 63, 6053-6058.
98. Reddy, G. M.; Chen, S.-Y.; Uang, B.-J. A facile synthesis of indolo[ 2,3-a]pyrrolo[3,4-c]carbazoles via oxidative photocyclization of bisindolylmaleimides. Synthesis, 2003, 497-500.
99. Hughes, I.; Nolan, W. P.; Raphael, R. A. Synthesis of the indolo[ 2,3-a]carbazole natural products staurosporinone and arcyriaflavin B. J. Chem. Soc., Per Tran 1, 1990, 2475-2480.
100. Lowinger, T. B.; Chu, J.; Spence, P. L. The total synthesis of (+-)-K252a. Tetrahedron Lett., 1995, 36, 8383-8386.
101. Moody, C. J.; Rahimtoola, K. F.; Porter, B.; Ross, B. C. Synthesis of the staurosporine aglycon. J. Org. Chem., 1992, 57, 2105-2114.
102. Gaudencio, S. P.; Santos, M. M. M.; Lobo, A. M.; Prabhakar, S. A short synthesis of staurosporinone (K-252c). Tetrahedron Lett., 2003, 44, 2577-2578.
103. Santos, M. M. M.; Lobo, A. M.; Prabhakar, S.; Marques, M. M. B. A new approach to N-protected staurosporinones. Tetrahedron Lett., 2004, 45, 2347-2349.
104. Wada, Y.; Nagasaki, H.; Tokuda, M.; Orito, K. Synthesis of NProtected Staurosporinones. J. Org. Chem., 2007, 72, 2008-2014.
105. Hudkins, R. L.; Park, C. H. Synthesis of indeno[2,1-a]pyrrolo[3,4-c] carbazole lactam regioisomers using ethyl cis-b-cyanoacrylate as a dienophile and lactam precursor. J. Heterocycl. Chem., 2003, 40, 135-142.
106. Hudkins, R. L.; Diebold, J. L.; Tao, M.; Josef, K. A.; Park, C. H.; Angeles, T. S.; Aimone, L. D.; Husten, J.; Ator, M. A.; Meyer, S. L.; Holskin, B. P.; Durkin, J. T.; Fedorov, A. A.; Fedorov, E. V.; Almo, S. C.; Mathiasen, J. R.; Bozyczko-Coyne, D.; Saporito, M. S.; Scott, R. W.; Mallamo, J. P. Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo [3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models. J. Med. Chem., 2008, 51, 5680-5689.
107. Underiner, T. L.; Ruggeri, B.; Aimone, L.; Albom, M.; Angeles, T.; Chang, H.; Hudkins, R. L.; Hunter, K.; Josef, K.; Robinson, C.; Weinberg, L.; Yang, S.; Zulli, A. TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs. Bioorg. Med. Chem. Lett., 2008, 18, 2368-2372.
108. Dandu, R.; Zulli, A. L.; Bacon, E. R.; Underiner, T.; Robinson, C.; Chang, H.; Miknyoczki, S.; Grobelny, J.; Ruggeri, B. A.; Yang, S.; Albom, M. S.; Angeles, T. S.; Aimone, L. D.; Hudkins, R. L. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases. Bioorg. Med. Chem. Lett., 2008, 18, 1916-1921.
109. Hudkins, R. L.; Johnson, N. W.; Angeles, T. S.; Gessner, G. W.; Mallamo, J. P. Synthesis and mixed lineage kinase activity of pyrrolocarbazole and isoindolone analogs of (+)K-252a. J. Med. Chem., 2007, 50, 433-441.
110. Becknell, N. C.; Zulli, A. L.; Angeles, T. S.; Yang, S.; Albom, M. S.; Aimone, L. D.; Robinson, C.; Chang, H.; Hudkins, R. L. Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGF-R2 dual inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5368-5372.
111. Wells, G. J.; Bihovsky, R.; Hudkins, R. L.; Ator, M. A.; Husten, J. Synthesis and structure-activity relationships of novel pyrrolocarbazole lactam analogs as potent and cell-permeable inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett., 2006, 16, 1151-1155.
112. Wood, J. L.; Stoltz, B. M.; Dietrich, H.-J.; Pflum, D. A.; Petsch, D. T. Design and implementation of an efficient synthetic approach to furanosylated indolocarbazoles: Total synthesis of (+)- and (-)-K252a. J. Am. Chem. Soc., 1997, 119, 9641-9651.
113. Wood, J. L.; Stoltz, B. M.; Goodman, S. N.; Onwueme, K. Design and Implementation of an Efficient Synthetic Approach to Pyranosylated Indolocarbazoles: Total Synthesis of (+)-RK286c, (+)-MLR-52, (+)-Staurosporine, and (-)-TAN-1030a. J. Am. Chem. Soc., 1997, 119, 9652-9661.
114. Kobayashi, Y.; Fujimoto, T.; Fukuyama, T. Stereocontrolled Total Synthesis of (+)-K252a. J. Am. Chem. Soc., 1999, 121, 6501-6502.
115. Prudhomme, M. Indolocarbazoles as anti-cancer agents. Curr. Pharma. Design, 1997, 3, 265-290.
116. Thompson, J. E.; Cubbon, R. M.; Cummings, R. T.; Wicker, L. S.; Frankshun, R.; Cunningham, B. R.; Cameron, P. M.; Meinke, P. T.; Liverton, N.; Weng, Y.; DeMartino, J. A. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg. Med. Chem. Lett., 2002, 12, 1219-1223.
117. Goulet, J. L.; Hong, X.; Sinclair, P. J.; Thompson, J. E.; Cubbon, R. M.; Cummings, R. T.; (Merck & Co., Inc., USA). Preparation of benzimidazo[4,5-f]isoquinolinones as inhibitors of Janus protein tyrosine kinases (Jak). Application: WO patent 2002-US23876, 2003011285.
118. Pedranzini, L.; Dechow, T.; Berishaj, M.; Comenzo, R.; Zhou, P.; Azare, J.; Bornmann, W.; Bromberg, J. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res., 2006, 66, 9714-9721.
119. Rodgers, J. D.; Robinson, D. J.; Arvanitis, A. G.; Maduskuie, T. P., Jr.; Shepard, S.; Storace, L.; Wang, H.; Rafalski, M.; Jalluri, R. K.; Combs, A. P.; Crawley, M. L.; (Incyte Corporation, USA). Preparation of tetracyclic inhibitors of Janus kinases for treating immune-related diseases and cancer. Application: WO patent 2005-US14494, 2005105814.
120. Garbaccio, R. M.; Huang, S.; Tasber, E. S.; Fraley, M. E.; Yan, Y.; Munshi, S.; Ikuta, M.; Kuo, L.; Kreatsoulas, C.; Stirdivant, S.; Drakas, B.; Rickert, K.; Walsh, E. S.; Hamilton, K. A.; Buser, C. A.; Hardwick, J.; Mao, X.; Beck, S. C.; Abrams, M. T.; Tao, W.; Lobell, R.; Sepp-Lorenzino, L.; Hartman, G. D. Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase. Bioorg. Med. Chem. Lett., 2007, 17, 6280-6285.
121. Lucet, I. S.; Fantino, E.; Styles, M.; Bamert, R.; Patel, O.; Broughton, S. E.; Walter, M.; Burns, C. J.; Treutlein, H.; Wilks, A. F.; Rossjohn, J. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood, 2006, 107, 176-183.
122. Wilks, A. F.; Burns, C. J.; Fantino, E.; Lucet, I.; Rossjohn, J.; Styles, M. L. Cytopia Research Pty. Ltd., Australia. Crystal structure of human JAK2 kinase domain bound to a high-affinity tetracyclic pyridone inhibitor and use of structural information for drug discovery. Application: WO patent AU583, 2006119542. 2006.
123. Young, J. R.; Haidle, A.; Tempest, P.; Machacek, M.; (Merck & Co., Inc., USA). Preparation of benzoimidazoisoquinolines as inhibitors of janus kinases. Application: WO patent 2007-US13255, 2007145957.
124. Shibuya, M.; Suzuki, Y.; Sugita, K.; Saito, I.; Sasaki, T.; Takakura, K.; Nagata, I.; Kikuchi, H.; Takemae, T.; Hidaka, H.; Nakashima; M. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J. Neurosurg., 1992, 76, 571-577.
125. Ito, K.; Shimomura, E.; Iwanaga, T.; Shiraishi, M.; Shindo, K.; Nakamura, J.; Nagumo, H.; Seto, M.; Sasaki, Y.; Takuwa, Y. Essential role of rho kinase in the Ca2+ sensitization of prostaglandin F(2alpha)-induced contraction of rabbit aortae. J. Physiol., 2003, 546, 823-836.
126. Uehata, M.; Ishizaki, T.; Satoh, H.; Ono, T.; Kawahara, T.; Morishita, T.; Tamakawa, H.; Yamagami, K.; Inui, J.; Maekawa, M.; Narumiya, S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature, 1997, 389, 990-994.
127. Shimokawa, H.; Seto, M.; Katsumata, N.; Amano, M.; Kozai, T.; Yamawaki, T.; Kuwata, K.; Kandabashi, T.; Egashira, K.; Ikegaki, I.; Asano, T.; Kaibuchi, K.; Takeshita, A. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc. Res., 1999, 43, 1029-1039.
128. Ono-Saito, N.; Niki, I.; Hidaka, H. H-series protein kinase inhibitors and potential clinical applications. Pharmacol. Ther., 1999, 82, 123-131.
129. Mueller, B. K.; Mack, H.; Teusch, N. Rho kinase, a promising drug target for neurological disorders. Nat. Rev. Drug Discov., 2005, 4, 387-398.
130. Masaoka, H.; Takasato, Y.; Nojiri, T.; Hayakawa, T.; Akimoto, H.; Yatsushige, H.; Toumori, H.; Miyazaki, Y.; Honma, M. Clinical effect of Fasudil hydrochloride for cerebral vasospasm following subarachnoid hemorrhage. Acta Neurochir. Suppl., 2001, 77, 209-211.
131. Shibuya, M.; Asano, T.; Sasaki, Y. Effect of Fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm. Acta Neurochir. Suppl., 2001, 77, 201-204.
132. Nagata, K.; Kondoh, Y.; Satoh, Y.; Watahiki, Y.; Yokoyama, E.; Yuya, H.; Hirata, Y.; Shishido, F.; Hatazawa, J.; Kanno, I.; et al. Effects of fasudil hydrochloride on cerebral blood flow in patients with chronic cerebral infarction. Clin. Neuropharmacol., 1993, 16, 501-510.
133. Suzuki, Y.; Shibuya, M.; Satoh, S.; Sugimoto, Y.; Takakura, K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg. Neurol., 2007, 68, 126-131; discussion 131-132.
134. Hidaka, H.; Suzuki, Y.; Shibuya, M.; Sasaki, Y. Isoquinolinesulfonamide: A specific inhibitor of rho-kinase and the clinical aspect of anti-rho-kinase therapy. Handb. Exp. Pharmacol., 2005, 167, 411-432.
135. Hidaka, H.; Asano, M.; Iwadare, S.; Matsumoto, I.; Totsuka, T.; Aoki, N.
136. Hidaka, H.; Yamaki, T.; Naka, M.; Tanaka, T.; Hayashi, H.; Kobayashi, R. Calcium-regulated modulator protein interacting agents inhibit smooth muscle calcium-stimulated protein kinase and ATPase. Mol. Pharmacol., 1980, 17, 66-72.
137. Hidaka, H.; Inagaki, M.; Kawamoto, S.; Sasaki, Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry, 1984, 23, 5036-5041.
138. Asano, T.; Suzuki, T.; Tsuchiya, M.; Satoh, S.; Ikegaki, I.; Shibuya, M.; Suzuki, Y.; Hidaka, H. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Br. J. Pharmacol., 1989, 98, 1091-1100.
139. Sasaki, Y.; Suzuki, M.; Hidaka, H. The novel and specific Rhokinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline) sulfonyl]-homopiperazine as a probing molecule for Rho-kinaseinvolved pathway. Pharmacol. Ther., 2002, 93, 225-232.
140. Nakamura, K.; Nishimura, J.; Hirano, K.; Ibayashi, S.; Fujishima, M.; Kanaide, H. Hydroxyfasudil, an active metabolite of fasudil hydrochloride, relaxes the rabbit basilar artery by disinhibition of myosin light chain phosphatase. J. Cereb. Blood Flow Metab., 2001, 21, 876-885.
141. Nakashima, M.; Kanemaru, M. Phase I study of AT- 877 (fasudil hydrochloride) in healthy subjects. Single and multiple administration. Jpn. Pharmacol. Ther., 1992, 20, S1559-S1585.
142. Jacobs, M.; Hayakawa, K.; Swenson, L.; Bellon, S.; Fleming, M.; Taslimi, P.; Doran, J. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J. Biol. Chem., 2006, 281, 260-268.
143. Hidaka, H.; Sone, T.; Sasaki, Y.; Sugihara, T. Asahi Chemical Industry Co., Ltd., Japan. Isoquinolinesulfonyl derivatives. Application: EP patent 102291, 61673. 1982.
144. Hidaka, H.; Sone, T. Asahi Chemical Industry Co., Ltd., Japan. Substituted isoquinolinesulfonyl compounds. Application: EP patent 116520, 187371. 1985.
145. Hidaka, H.; Tanaka, T.; Ito, Y.; Kato, H.; Euchu, E.; Mitani, K.; Sakurai, S.; (Hokuriku Pharmaceutical Co., Ltd., Japan). 1-Hydroxyisoquinoline- 4-sulfonamide derivatives as circulatory drugs. Application: JP patent 1987-43118, 63211267.
146. Hidaka, H.; Morikawa, Y. Asahi Chemical Industry Co., Ltd., Japan. Preparation of isoquinolinesulfonamide as cardiovascular agents and smooth muscle relaxants. Application: JP patent 251974, 62111981. 1985.
147. Hidaka, H.; Morikawa, Y. Asahi Chemical Industry Co., Ltd., Japan. Preparation of 5-isoquinolinesulfonamide derivatives as smooth muscle relaxants. Application: JP patent 240646, 62103066. 1985.
148. Hidaka, H.; Sone, T. Asahi Chemical Industry Co., Ltd., Japan. Preparation of 1-chloro-5-isoquinolinesulfonic acid as intermediate for cardiovascular agents. Application: JP patent 142790, 63002980. 1986.
149. Kawakubo, H.; Sasaki, Y. Asahi Chemical Ind, Japan. Preparation and determination of isoquinolinesulfonamide derivatives. Application: JP patent 173242, 09020773. 1995.
150. Kawakubo, H.; Takahashi, N. Asahi Chemical Industry Co., Ltd., Japan. Preparation of 1-(5-isoquinolinesulfonyl)homopiperazine in hydrophilic solvents. Application: JP patent 342860, 11171885. 1997.
151. Hidaka, H.; Tamura, M.; Nakao, H.; Sigyo, H.; Yamada, H.; Ozawa, T.; Yoshizaki, H. D. Western Therapeutics Institute, Inc., Japan. Preparation of homopiperazine compounds containing isoquinoline-5-sulfonyl moiety as selective Rho-kinase inhibitors. Application: WO patent JP308574, 2006115247. 2006.
152. Hidaka, H.; Tamura, M.; Nakao, H.; Shigyo, H.; Yamada, H.; Ozawa, T.; Yoshizaki, E. D.Western Therapeutics Institute, Japan. Preparation of isoquinolines containing homopiperazine moiety for inhibiting osteoclast differentiation. Application: JP patent 50365, 2007224000. 2006.
153. Hidaka, H.; Tamura, M.; Nakao, H.; Shigyo, H.; Yamada, H.; Ozawa, T.; Yoshizaki, E. D.Western Therapeutics Institute, Japan. Isoquinolines, and pharmaceuticals containing them. Application: JP patent 58867, 2007238458. 2006.
154. Islam, I.; Johns, A.; Mylecraine, L.; Pagila, R.; Phillips, G.; Zentel, H. J.; Sabramanyam, B. Schering Aktiengesellschaft, Germany. Preparation of prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine. Application: WO patent US16919, 2004106325. 2004.
155. Li, R.; Xue, L.; Zhu, T.; Jiang, Q.; Cui, X.; Yan, Z.; McGee, D.; Wang, J.; Gantla, V. R.; Pickens, J. C.; McGrath, D.; Chucholowski, A.; Morris, S. W.; Webb, T. R. Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. J. Med. Chem., 2006, 49, 1006-1015.
156. Zhu, T.; Yan, Z.; Chucholowski, A.; Webb, T. R.; Li, R. Polymer-supported synthesis of pyridone-focused libraries as inhibitors of anaplastic lymphoma kinase. J. Comb. Chem., 2006, 8, 401-409.
157. Snow, R. J.; Cardozo, M. G.; Morwick, T. M.; Busacca, C. A.; Dong, Y.; Eckner, R. J.; Jacober, S.; Jakes, S.; Kapadia, S.; Lukas, S.; Panzenbeck, M.; Peet, G. W.; Peterson, J. D.; Prokopowicz, A. S., 3rd; Sellati, R.; Tolbert, R. M.; Tschantz, M. A.; Moss, N. Discovery of 2-phenylamino-imidazo[4,5-h] isoquinolin-9-ones: a new class of inhibitors of lck kinase. J. Med. Chem., 2002, 45, 3394-3405.
158. Goldberg, D. R.; Butz, T.; Cardozo, M. G.; Eckner, R. J.; Hammach, A.; Huang, J.; Jakes, S.; Kapadia, S.; Kashem, M.; Lukas, S.; Morwick, T. M.; Panzenbeck, M.; Patel, U.; Pav, S.; Peet, G. W.; Peterson, J. D.; Prokopowicz, A. S., 3rd; Snow, R. J.; Sellati, R.; Takahashi, H.; Tan, J.; Tschantz, M. A.; Wang, X. J.; Wang, Y.; Wolak, J.; Xiong, P.; Moss, N. Optimization of 2-phenylaminoimidazo[ 4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase. J. Med. Chem., 2003, 46, 1337-1349.
159. Bach, S.; Knockaert, M.; Reinhardt, J.; Lozach, O.; Schmitt, S.; Baratte, B.; Koken, M.; Coburn, S. P.; Tang, L.; Jiang, T.; Liang, D. C.; Galons, H.; Dierick, J. F.; Pinna, L. A.; Meggio, F.; Totzke, F.; Schachtele, C.; Lerman, A. S.; Carnero, A.; Wan, Y.; Gray, N.; Meijer, L. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem., 2005, 280, 31208-31219.
160. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C. J.; McLauchlan, H.; Klevernic, I.; Arthur, J. S.; Alessi, D. R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update. Biochem. J., 2007, 408, 297-315.
161. Bantscheff, M.; Eberhard, D.; Abraham, Y.; Bastuck, S.; Boesche, M.; Hobson, S.; Mathieson, T.; Perrin, J.; Raida, M.; Rau, C.; Reader, V.; Sweetman, G.; Bauer, A.; Bouwmeester, T.; Hopf, C.; Kruse, U.; Neubauer, G.; Ramsden, N.; Rick, J.; Kuster, B.; Drewes, G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol., 2007, 25, 1035-1044.
162. Fedorov, O.; Marsden, B.; Pogacic, V.; Rellos, P.; Muller, S.; Bullock, A. N.; Schwaller, J.; Sundstrom, M.; Knapp, S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 20523-20528.
163. Goldstein, D. M.; Gabriel, T. Pathway to the clinic: Inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr. Top. Med. Chem., 2005, 5, 1017-1029.
164. Manfredi, M. G.; Ecsedy, J. A.; Meetze, K. A.; Balani, S. K.; Burenkova, O.; Chen, W.; Galvin, K. M.; Hoar, K. M.; Huck, J. J.; LeRoy, P. J.; Ray, E. T.; Sells, T. B.; Stringer, B.; Stroud, S. G.; Vos, T. J.; Weatherhead, G. S.; Wysong, D. R.; Zhang, M.; Bolen, J. B.; Claiborne, C. F. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 4106-4111.
165. Melnick, J. S.; Janes, J.; Kim, S.; Chang, J. Y.; Sipes, D. G.; Gunderson, D.; Jarnes, L.; Matzen, J. T.; Garcia, M. E.; Hood, T. L.; Beigi, R.; Xia, G.; Harig, R. A.; Asatryan, H.; Yan, S. F.; Zhou, Y.; Gu, X. J.; Saadat, A.; Zhou, V.; King, F. J.; Shaw, C. M.; Su, A. I.; Downs, R.; Gray, N. S.; Schultz, P. G.; Warmuth, M.; Caldwell, J. S. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 3153-3158.
166. Lai, J. Y.; Langston, S.; Adams, R.; Beevers, R. E.; Boyce, R.; Burckhardt, S.; Cobb, J.; Ferguson, Y.; Figueroa, E.; Grimster, N.; Henry, A. H.; Khan, N.; Jenkins, K.; Jones, M. W.; Judkins, R.; Major, J.; Masood, A.; Nally, J.; Payne, H.; Payne, L.; Raphy, G.; Raynham, T.; Reader, J.; Reader, V.; Reid, A.; Ruprah, P.; Shaw, M.; Sore, H.; Stirling, M.; Talbot, A.; Taylor, J.; Thompson, S.; Wada, H.; Walker, D. Preparation of kinase-biased compounds in the search for lead inhibitors of kinase targets. Med. Res. Rev., 2005, 25, 310-330.
167. Li, B.; Liu, Y.; Uno, T.; Gray, N. Creating chemical diversity to target protein kinases. Comb. Chem. High Throughput Screening, 2004, 7, 453-472.
168. Liao, J. J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem., 2007, 50, 409-424.
169. Dumas, J. Protein kinase inhibitors: emerging pharmacophores 1997 - 2000. Expert Opin. Ther. Pat., 2001, 11, 405-429.
170. Bridges, A. J. Chemical inhibitors of protein kinases. Chem. Rev., 2001, 101, 2541-2572.